Disease severity in patients with simultaneous influenza and bacterial pneumonia

Internal Medicine

Volumn 46, Issue 13, 2007, Pages 953-958

  Seki, Masafumi ^a,b,c   Kosai, Kosuke ^a,b,c   Yanagihara, Katsunori ^b   Higashiyama, Yasuhito ^a   Kurihara, Shintaro ^b   Izumikawa, Koichi ^a,b   Miyazaki, Yoshitsuga ^a,b   Hirakata, Yoichi ^a,b   Tashiro, Takayoshi ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITAKYUSHU CITY YAHATA HOSPITAL   (Japan)

Author keywords

Bacterial pneumonia; Co infection; Influenza virus

Indexed keywords

C REACTIVE PROTEIN; VIRUS ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; ASTHMA; BACTERIAL PNEUMONIA; BODY TEMPERATURE; CEREBROVASCULAR ACCIDENT; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COLLAGEN DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FREQUENCY ANALYSIS; HEART FAILURE; HEART RATE; HUMAN; INFLUENZA; INFLUENZA VIRUS; LIVER DISEASE; LUNG INFILTRATE; LUNG TUBERCULOSIS; MALE; NEOPLASM; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; SUPERINFECTION; THORAX RADIOGRAPHY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROBABILITY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC;

EID: 34547924444     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6364     Document Type: Article

References (32)

1. Murphy BR, Webster R. Fields Virology, Third Edition. Lippincott-Raven Publishers, Philadelphia, 1996.
2. Infectious Diseases Society of America. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 31: 347-382, 2000.
3. Glezen WP, Greenberg S, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283: 499-505, 2000.
4. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180, 2005.
5. American Thoracic Society. Guidelines for management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 63: 1730-1754, 2001.
6. McCullers JA, Rehg J. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 186: 341-350, 2002.
7. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190: 519-526, 2004.
8. McCullers JA, Bartmess K. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 187: 1000-1009, 2004.
9. Peltola VT, Murti K, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 192: 249-257, 2005.
10. van der Sluijs KF, van Elden L, Nijhuis M, et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 290: L194-L199, 2006.
11. van der Sluijs KF, van Elden L, Nijhuis M, et aL IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172: 7603-7609, 2004.
12. Seki M, Yanagihara K, Higashiyama Y, et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 24: 143-149, 2004.
13. Seki M, Higashiyama Y, Tomono K, et al. Acute infection with influenza virus enhances susceptibility to fatal pneumonia following Streptococcus pneumoniae infection in mice with chronic pulmonary colonization with Pseudomonas aeruginosa. Clin Exp Immunol 137: 35-40, 2004.
14. Abramson JS, Giebink G, Mills EL, Quie PG. Polymorphonuclear leukocyte dysfunction during influenza virus infection in chinchillas. J Infect Dis 143: 836-845, 1981.
15. Abramson JS, Lyles D, Heller KA, Bass DA. Influenza A virus-induced polymorphonuclear leukocyte dysfunction. Infect Immun 37: 794-799, 1982.
16. Yanagihara K, Ohtsu Y, Ohno H, et al. Clinical characteristics of pneumonia caused by penicillin resistant and sensitive Streptococcus pneunoniae in Japan. Intern Med 43: 1029-1033, 2004.
17. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 18: S45-S48, 2001.
18. Motomura K, Masaki H, Terada M, et al, Usefulness of the Japanese Respiratory Society guidelines for community pneumonia: a retrospective analysis of community-acquired pneumonia between 2000 and 2002 in a general hospital. Respirology 10: 208-214, 2005.
19. Taubenberger JK, Reid A, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 275: 1793-1796, 1997.
20. Reid AH, Fanning T, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA 96: 1651-1656, 1999.
21. Chan MC, Cheuning C, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 6: 135-148, 2005.
22. Marien M, Decostere A, Martel A, Chiers K, Froyman R, Nauwynck H. Synergy between avian pneumovirus and Ornithobacterium rhinotracheale in turkeys. Avian Pathol 2005 34: 204-211, 2005.
23. Gershwin LJ, Berghaus L, Arnold K, Anderson ML, Corbeil LB. Immune mechanisms of pathogenetic synergy in concurrent bovine pulmonary infection with Haemophilus somnus and bovine respiratory syncytial virus. Vet Immunol Immunopathol 15: 119-130, 2005.
24. Louria DB, Blumenfeld H, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 21: 213-265, 1959.
25. O'Brien KL, Walters M, Sellman J, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 30: 784-789, 2000.
26. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 31: 2566-2573, 2001.
27. Scheiblauer H, Reinacher M, Tashiro M, Rott R. Interactions between bacteria and influenza A virus in the development of influenza pneumonia. J Infect Dis 166: 783-791, 1992.
28. Sato K, Suga M, Akaike T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med 157: 853-857, 1998.
29. Pang G, Clancy R, Cong M, Ortega M, Zhigang R, Reeves G. Influenza virus inhibits lysozyme secretion by sputum neutrophils in subjects with chronic bronchial sepsis. Am J Resp Crit Care Med 161: 718-722, 2000.
30. Beckham JD, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect 50: 1098-1196, 2005.
31. Oliveira EC, Marik P, Colice G. Influenza pneumonia: a descriptive study. Chest 119: 1717-1723, 2001.
32. Matsukura S, Kokubo F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J. Allergy Clin Immunol 98: 1080-1087, 1996.